文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Zerlasiran——靶向脂蛋白(a)的小干扰RNA:2期随机临床试验

Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

这项多中心2期随机临床试验在稳定型动脉粥样硬化性心血管疾病且脂蛋白(a)≥125 nmol/L的患者中评估zerlasiran的疗效。结果显示,与安慰剂组相比,zerlasiran各给药方案在36周内使脂蛋白(a)时间平均百分比降幅均超过80%,最常见治疗相关不良事件为注射部位反应,未发生与研究药物相关的严重不良事件。

要点

  • 在稳定型ASCVD且脂蛋白(a)≥125 nmol/L患者中,zerlasiran各方案36周内脂蛋白(a)时间平均降幅均超过80%。
  • 最常见治疗相关不良事件为注射部位反应,给药后首日轻度疼痛发生率为2.3%至7.1%。
  • 17例患者发生20起严重不良事件,均认为与研究药物无关。

核心结论

  • Zerlasiran耐受性良好,在ASCVD患者36周治疗期间使脂蛋白(a)时间平均浓度降低超过80%。

研究设计与样本

  • 多中心2期随机临床试验,在欧洲和南非26个中心于2023年1月3日至2023年4月27日纳入稳定型ASCVD且血清脂蛋白(a)≥125 nmol/L的患者,末次随访至2024年7月1日。
  • 178例患者随机接受安慰剂每16周1次共3剂(n=23)或每24周1次共2剂(n=24),或zerlasiran 450 mg每24周1次共2剂(n=45)、300 mg每16周1次共3剂(n=42)、300 mg每24周1次共2剂(n=44);172例完成试验。
  • 主要结局为从基线至36周脂蛋白(a)浓度的时间平均百分比变化,随访至60周。

主要发现

  • 患者平均(SD)年龄63.7(9.4)岁,46例(25.8%)为女性,基线脂蛋白(a)浓度中位数(IQR)为213(177-282)nmol/L。
  • 与合并安慰剂组相比,450 mg每24周组、300 mg每16周组和300 mg每24周组从基线至36周脂蛋白(a)时间平均百分比变化的最小二乘均值分别为-85.6%(95%CI,-90.9%至-80.3%)、-82.8%(95%CI,-88.2%至-77.4%)和-81.3%(95%CI,-86.7%至-76.0%)。
  • 第36周脂蛋白(a)百分比变化中位数(IQR):450 mg每24周组为-94.5%(-97.3%至-84.2%),300 mg每16周组为-96.4%(-97.7%至-92.3%),300 mg每24周组为-90.0%(-93.7%至-81.3%)。
  • 最常见治疗相关不良事件为注射部位反应,给药后首日轻度疼痛发生于2.3%至7.1%的受试者。
  • 17例患者共发生20起严重不良事件,均认为与研究药物无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. OBJECTIVE: To evaluate the effects of zerlasiran, a small-interfering RNA targeting hepatic synthesis of apolipoprotein(a), on lipoprotein(a) serum concentration. DESIGN, SETTING, AND PARTICIPANTS: A multicenter trial in patients with stable ASCVD with serum lipoprotein(a) concentrations greater than or equal to 125 nmol/L at 26 sites in Europe and South Africa between January 3, 2023, and April 27, 2023, with last follow-up on July 1, 2024. INTERVENTIONS: Participants randomized to receive a subcutaneous dose of placebo every 16 weeks for 3 doses (n = 23) or every 24 weeks for 2 doses (n = 24) or zerlasiran 450 mg every 24 weeks for 2 doses (n = 45), 300 mg every 16 weeks for 3 doses (n = 42), or 300 mg every 24 weeks for 2 doses (n = 44). MAIN OUTCOME AND MEASURES: The primary outcome was the time-averaged percent change in lipoprotein(a) concentration from baseline to 36 weeks, with follow-up to 60 weeks. RESULTS: Among 178 patients, mean (SD) age was 63.7 (9.4) years, 46 (25.8%) were female, with a median (IQR) baseline lipoprotein(a) concentration of 213 (177-282) nmol/L; 172 patients completed the trial. Compared with the pooled placebo group, the least-squares mean time-averaged percent change in lipoprotein(a) concentration from baseline to week 36 was -85.6% (95% CI, -90.9% to -80.3%), -82.8% (95% CI, -88.2% to -77.4%), and -81.3% (95% CI, -86.7% to -76.0%) for the 450 mg every 24 weeks, 300 mg every 16 weeks, and 300 mg every 24 weeks groups, respectively. Median (IQR) percent change in lipoprotein(a) concentration at week 36 was -94.5% (-97.3% to -84.2%) for the 450 mg every 24 weeks group, -96.4% (-97.7% to -92.3%) for the 300 mg every 16 weeks group, and -90.0% (-93.7% to -81.3%) for the 300 mg every 24 weeks group. The most common treatment-related adverse effects were injection site reactions, with mild pain occurring in 2.3% to 7.1% of participants in the first day following drug administration. There were 20 serious adverse events in 17 patients, none considered related to the study drug. CONCLUSIONS: Zerlasiran was well-tolerated and reduced time-averaged lipoprotein(a) concentration by more than 80% during 36 weeks of treatment in patients with ASCVD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05537571.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Nissen SE, Wang Q, Nicholls SJ, et al. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA. 2024. PMID: 39556769. doi:10.1001/jama.2024.21957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。